Jordan R. Hansford
A5027426012- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Chromatin Remodeling and Cancer
- Epigenetics and DNA Methylation
- Brain Metastases and Treatment
- Neurofibromatosis and Schwannoma Cases
- ATP Synthase and ATPases Research
- Cancer, Hypoxia, and Metabolism
- Meningioma and schwannoma management
- Hedgehog Signaling Pathway Studies
- Protein Degradation and Inhibitors
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Renal and related cancers
- Childhood Cancer Survivors' Quality of Life
- Cancer Immunotherapy and Biomarkers
- Ocular Oncology and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Genomic variations and chromosomal abnormalities
- Melanoma and MAPK Pathways
- Lung Cancer Treatments and Mutations
- Vascular Malformations Diagnosis and Treatment
- Circular RNAs in diseases
The University of Adelaide
2022-2025
Centre for Cancer Biology
2022-2025
South Australian Health and Medical Research Institute
2022-2025
Women's and Children's Hospital
2012-2025
MacEwan University
2025
Royal Children's Hospital
2015-2024
Murdoch Children's Research Institute
2016-2024
The University of Melbourne
2016-2024
Rush University Medical Center
2024
Children's Cancer Institute Australia
2022-2023
Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) a highly penetrant childhood cancer syndrome often resulting in GBM characterized by high mutational burden. Evidence suggests that mutation and neoantigen loads are associated response to immune checkpoint inhibition.We performed exome sequencing prediction on 37 bMMRD cancers compared them adult brain neoplasms. Neoantigen was responsive from multiple tissues. Two...
Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments the central nervous system (supratentorial brain, posterior fossa, spinal cord). These advances motivated a consensus meeting to discuss: (1) utility current histologic grading criteria, (2) integration molecular-based stratification schemes in future clinical trials for patients with (3) therapy context molecular...
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors a higher mortality rate, while high-grade better outcome. However, we little understanding of their biology therefore cannot explain this nor what constitutes optimal management. Here report comprehensive genetic analysis an international cohort clinically annotated infant gliomas, revealing 3 subgroups. Group 1 arise the cerebral hemispheres harbor alterations receptor tyrosine...
Abstract Purpose: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor. Patients with BRAF V600 mutation–positive pLGG may benefit from treatment dabrafenib. Part 2 of a phase I/IIa study, open-label study (NCT01677741) explores activity and safety dabrafenib in these patients. Methods: ages 1 to <18 years who had V600–mutant solid tumors (≥1 evaluable lesion) recurrent, refractory, or progressive disease after ≥1 standard therapy were treated oral 3.0 5.25...
SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants genetic alterations in medulloblastoma.
Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was evaluate the efficacy safety larotrectinib in primary central nervous system (CNS) tumors.Patients CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. endpoint investigator-assessed objective response rate (ORR).As July 2020, 33 identified (median age: 8.9 years;...
Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and combination trametinib) shown efficacy recurrent V600 mutations, findings that warrant further evaluation this first-line therapy. phase 2 trial, patients mutations who were scheduled receive therapy randomly assigned 2:1 ratio plus trametinib or chemotherapy (carboplatin vincristine). The primary...
Abstract Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading (MMRD and PPD) in children harbour the highest mutational microsatellite insertion–deletion (MS-indel) burden humans. MMRD PPD cancers are commonly lethal due to inherent resistance chemo-irradiation. Although immune checkpoint inhibitors (ICIs) have failed benefit previous studies, we hypothesized that hypermutation caused by will improve outcomes following ICI treatment these patients. Using an...
The large diversity of central nervous system (CNS) tumor types in children and adolescents results disparate patient outcomes renders accurate diagnosis challenging. In this study, we prospectively integrated DNA methylation profiling targeted gene panel sequencing with blinded neuropathological reference diagnostics for a population-based cohort more than 1,200 newly diagnosed pediatric patients CNS tumors, to assess their utility routine neuropathology. We show that the multi-omic...
Abstract BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 ( n = 77) of ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated efficacy oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m − once weekly; 600 maximum) patients with -altered, relapsed/refractory pLGG. 60) is an extension cohort, which provided treatment access for -altered pLGG after arm closure. Based on independent review,...
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is only established treatment, with median patient survival 9 to 11 months. ONC201 a DRD2 antagonist and ClpP agonist that has shown preclinical emerging clinical efficacy in DMG. However, further work needed identify mechanisms response DIPGs treatment determine whether recurring genomic features influence response. Using systems-biological approach,...
Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which will benefit most from precision-guided (PGT). Here we report consecutive data 384 high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Children (PRISM) trial. A total 256 (67%) received PGT recommendations and 110 (29%) a...
Medulloblastoma is curable in approximately 70% of patients. Over the past decade, progress improving survival using conventional therapies has stalled, resulting reduced quality life due to treatment-related side effects, which are a major concern survivors. The vast amount genomic and molecular data generated over last 5-10 years encourages optimism that improved risk stratification new targets will improve outcomes. It now clear medulloblastoma not single-disease entity, but instead...
PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes current chemoradiotherapy strategies. Our aim was to study the role of targeted inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients V600E–mutated glioma treated across 29 centers multiple countries. RESULTS Sixty-seven were (pediatric low-grade [PLGGs], n = 56; high-grade [PHGGs], 11) for up 5.6 years. Objective responses...